Abstract: AIM: To investigate the effect of PXR11193T＞C,8055 C＞T and PXR^*1B (contain 11193T＞C and 8055C＞T) on the steady-state trough concentration and antihypertensive effect of amlodipine in essential hypertension patients. METHODS: Genotyping of PXR11193T＞C and 8055 C＞T were determined by pyrosequencing sequenator. PXR^*1B was analyzed by PHASE V.2.1. 62 essentialhypertension patients rolled the clinical trial. They were treated with amlodipine for 8 weeks, according to once a day, 5 mg per time in every morning. Blood pressure was measured at 0, 4, 8-week. At 8-week the venous blood samples were collected before amlodipine administration. Plasma was used to determined concentration of amlodipine by HPLC-MS/MS. Statistical analyses were performed by the SPSS 13.0 software for Windows. RESULTS: 61 of patients finished the clinical trial and the effective power of amlodipine was 63.9％. There was no significantly difference of the steady-state trough concentration and antihypertensive effect of amlodipine among genotypes of PXR11193T＞C,8055 C＞T and PXR^*1B(P＞0.05). CONCLUSION: PXR polymorphisms does not significantly affect the steady-state trough concentration and antihypertensive effect of amlodipine in essential hypertension patients.

Key words: Pregnane X receptor, Gene polymorphism, Amlodipine, Concentration, Antihypertensive